Jefferies raises JPMorgan stock price target on deposit growth

Jefferies raised its JPMorgan Chase (JPM) price target to $350 from $340 while keeping a Hold rating after a strong reported quarter. JPM posted Q2’26 earnings of $7.70/share on $57.35B revenue versus $5.55/share and $50.61B expected, driven by markets, investment banking, consumer banking, and wealth management; investment banking fees rose ~30% YoY and markets revenue grew over 30%. Jefferies also lifted fiscal 2026 core net interest income guidance and increased its expense guidance, citing better-than-expected deposit growth (+7% YoY, with consumer deposits +3%), though JPM faces continued regulatory-capital pressure per CEO Jamie Dimon’s comments.

Analysis

The market read-through is less about one quarter and more about the durability of revenue mix. JPM is showing that the big-bank model can still compound when capital markets and fee lines reaccelerate, which matters because those businesses have much higher incremental margins than plain-vanilla spread income. That shifts the relative-value debate toward money-center banks with diversified balance sheets and away from lenders whose earnings still depend mostly on deposit beta and credit normalization.

The second-order winner is likely the large-bank complex more broadly, but not evenly: JPM has the best ability to absorb higher compliance, tech, and compensation costs while still defending ROTCE. Regionals and smaller banks do not get the same benefit from market activity, and they remain more exposed to funding competition and CRE reserve creep, so this is constructive for JPM vs KRE rather than a broad bullish call on all banks.

The main risk is that investors extrapolate a cyclical rebound in markets and ECM into a structural step-up in earnings power. If vol compresses or issuance cools over the next 1-3 months, fee growth can normalize quickly, while the higher expense guide limits operating leverage. The real catalyst for a rerating over 6-18 months is not just earnings beats; it is any credible signal that capital rules or buyback constraints ease, because that is what unlocks multiple expansion beyond a simple EPS upgrade cycle.

Contrarian take: the consensus may be underestimating how much of JPM's upside is already visible in analyst revisions, and overestimating how much regulatory rhetoric changes actual capital outcomes. If regulators stay unchanged, the stock can still grind higher, but the upside is more likely to come from relative outperformance than a clean expansion in valuation multiple.

Key Decisions for Investors

• Long JPM / short KRE on any 2-3% post-earnings pullback; thesis is that JPM's capital-markets and deposit franchise monetizes the cycle better than regionals while KRE still faces funding and CRE overhang. Target 6-10% spread outperformance over 1-3 months; stop if JPM gives back the earnings gap and KRE outperforms on a curve-steepening move.
• Buy JPM 3-6 month call spreads rather than stock if you want regulatory-upside exposure without overpaying for near-term volatility; the trade works if buyback-capital commentary or analyst EPS revisions keep drifting higher. Fails if expense guidance keeps ratcheting up faster than revenue revisions.
• Use JPM strength as a hedge against weaker bank beta: pair long JPM against short a basket proxy like KBE or KRE to isolate quality and scale. This is the cleaner expression if the thesis is 'money-center share gain, not broad bank re-rating.'
• Watch for reversal triggers: a downshift in ECM/IB pipeline, a decline in market revenue normalization, or a post-earnings move in JPM back below the prior breakout zone. If any of those hit within the next 4-8 weeks, cut exposure because the quarter may have marked peak cyclical optimism.